X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EPX-100 is a first-generation antihistamine which was safely used to treat itch between 1950 and 1970. EPX-100 was found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish models for Dravet Syndrome.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: EPX-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
Details:
EPX-200 is a weight gain management drug that acts via modulation of serotonin (5HT) signaling pathways. EPX-200 was firstly identified in a zebrafish disease model for Dravet Syndrome.
Lead Product(s): Lorcaserin HCl
Therapeutic Area: Neurology Product Name: EPX-200
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
This study will test the efficacy and safety of EPX-100 in children suffering from Dravet Syndrome. EPX-100 is a first-generation antihistamine and found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish models.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: EPX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting 24 patients to complete the study.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: EPX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
Details:
This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: EPX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GreenLight Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
This Phase 1 study successfully confirmed that EPX-100 is safe, well-tolerated, and does not show any clinically significant abnormalities among equal numbers of male and female subjects.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
